Figures & data
Table 1. Features in Those Exposed to Sarin in Japan in 1994 and 1995 (Abstract 9)
Figure 1. TK–TD relationships in phenobarbital poisonings. (Abstract 12)
Figure 2. TK–TD relationships in meprobamate poisonings. (Abstract 12)
Table 1
Table 1. Answers (n=813) (Abstract 53)
Table 1. Sensitivity and Specificity Related to Fatal Outcome of ALT, Bilirubin, Thromboplastin Time and Creatinine from Day 2 to 5 After Ingestion (Abstract 58)
Table 1. Botanicals Implicated in Fatalities (AAPCC TESS 1983–2000) (Abstract 61)
Table 1. Viper Bites in Italy (Abstract 62)
Table 2. Snake Bites in Sri Lanka (Abstract 62)
Table 1. (Abstract 73)
Table 1. Clinical and Toxicokinetic Data in Seven Patients with MDMA Toxicity (Abstract 76)
Table 1. The Symptoms of Oesophagus and Stomach Lesions in Acetic Acid Poisoned Patients (Abstract 80)
Table 1. (Abstract 87)
Figure. (Abstract 98)
Figure. (Abstract 99)
Figure 1. Readmission rate according to age at first presentation. (Abstract 105)
Table 1. Poisoning Admissions and Deaths per Toxic Group (Abstract 109)
Table 1. Comparison of Toxicity of 5 SSRIs (Abstract 119)
Table 1. Agents Involved in QTc and QRS Changes (Abstract 120)
Table 1. (Abstract 124)
Table 1. Contents (Mean Values) of Cu and Fe in Biopsy Liver Specimens and Respective Oscillation (Maximum and Minimum Values)
Table 1. Number of Paracetamol Tablets Purchased at Different Outlets in South London (Abstract 131)
Table 1. Symptomatic Patients (Abstract 137)
Table 1. Toxicokinetic–Toxicodynamic Data in a Patient with Modified-Release Amitriptyline Poisoning (Abstract 138)
Table 1. Notified Subjective Complaints and Physical Findings Grouped by Agent (Abstract 141)
Figure 1. 800–1200 mg lidocaine subcutaneous between 21:30 and 22:00h: toxic range >6 mg/L. (Abstract 149)
Table 1. (Abstract 152)
Figure 1. Number of poisonings involving opiates/opioids recorded in the patient database of all interventions by SAMU 93. (Abstract 154)
Figure 2. Evolution of the annual number of detection of opiates/opioids admitted in our Intensive Care Unit. (Abstract 154)
Table 1. (Abstract 155)
Table 1. (Abstract 156)
Table 1. (Abstract 161)
Table 2. Staffing at NPISL 1993–2001 (Abstract 161)
Table 1. Availability of Antidotes Sufficient to Treat 1 Seriously Poisoned 70 kg Patient (Abstract 163)
Table 1. Adsorption of Carbamazepine and Aspirin to the Study (SCN and SICS) and Control (Adsorba) Carbons (Abstract 186)
Figure 1. Arsenic urinary concentration in comparison with urinary volume. (Abstract 188)
Table 1. Arsenic Serum- and Urinary Concentration as Well as Arsenic Clearance During Chelation Therapy with DMPS (Dimercaptopropane Sulfonate) in Acute Arsenic Poisoning (Abstract 188)
Figure 1. Concentration of arsenic in serum and urine day 1–54. Treatment: DMSA 600 mg orally three times daily. (Abstract 189)
Table 1. (Abstract 207)